Nephros (NASDAQ:NEPH – Get Free Report) and INLIF (NASDAQ:INLF – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk and valuation.
Volatility & Risk
Nephros has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500. Comparatively, INLIF has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500.
Earnings and Valuation
This table compares Nephros and INLIF”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nephros | $18.79 million | 1.83 | $1.19 million | $0.11 | 29.36 |
| INLIF | $18.41 million | 3.29 | -$5.45 million | N/A | N/A |
Nephros has higher revenue and earnings than INLIF.
Analyst Ratings
This is a summary of recent recommendations for Nephros and INLIF, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nephros | 0 | 1 | 1 | 0 | 2.50 |
| INLIF | 1 | 0 | 0 | 0 | 1.00 |
Nephros currently has a consensus price target of $6.00, indicating a potential upside of 85.76%. Given Nephros’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Nephros is more favorable than INLIF.
Institutional and Insider Ownership
41.1% of Nephros shares are owned by institutional investors. 6.7% of Nephros shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares Nephros and INLIF’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nephros | 6.35% | 12.22% | 9.38% |
| INLIF | N/A | N/A | N/A |
Summary
Nephros beats INLIF on 11 of the 12 factors compared between the two stocks.
About Nephros
Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also manufactures and sells water filters that enhance the taste and odor of water, as well as reduce biofilm, cysts, particulates, and scale build-up in downstream equipment. It markets its products to food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.
About INLIF
INLIF Ltd. is a holding company, which engages in the development of injection molding machine-dedicated manipulator arms. Its products include: Three-axis robot, Five-axis robot and bull head type manipulator. The company was founded on January 4, 2023 and is headquartered in Quanzhou, China.
Receive News & Ratings for Nephros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nephros and related companies with MarketBeat.com's FREE daily email newsletter.
